| HPAF-II |
| RS Metzgar |
| Biosafety Level: | 1 |
| frozen |
| Medium & Serum: | See Propagation |
| adherent |
| Homo sapiens |
| epithelial
|
| Organ: pancreas
Disease: adenocarcinoma |
| mucin |
| In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location. |
| Yes |
| Blood Type A; Rh-; HLA A1, A10 (W34), B8, W22, Cw3 |
| Amelogenin: X
CSF1PO: 10,11
D13S317: 12
D16S539: 11,13
D5S818: 11,13
D7S820: 10,13
F13A01: 5,17
F13B: 8,10
FESFPS: 11,12
LPL: 10
THO1: 9
TPOX: 8
vWA: 17 |
| 44 years |
| male |
| Caucasian |
| Propagation: | ATCC complete growth medium: The base medium for this cell line is ATCC-formulated Eagle's Minimum Essential Medium, Catalog No. 30-2003. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Temperature: 37.0°C |
| Protocol: - Remove and discard culture medium.
- Briefly rinse the cell layer with 0.25% (w/v) Trypsin- 0.53 mM EDTA solution to remove all traces of serum which contains trypsin inhibitor.
- Add 2.0 to 3.0 ml of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually within 5 to 15 minutes).
Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37�C to facilitate dispersal. - Add 6.0 to 8.0 ml of complete growth medium and aspirate cells by gently pipetting.
- Add appropriate aliquots of the cell suspension to new culture vessels.
- Incubate cultures at 37�C.
Subcultivation Ratio: A subcultivation ratio of 1:2 to 1:3 is recommended
Medium Renewal: 2 to 3 times per week |
| Freeze medium: Complete growth medium 95%; DMSO, 5%
Storage temperature: liquid nitrogen vapor phase |
| Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2003
recommended serum:ATCC 30-2020 |
| 21871: . Monoclonal antibodies in cancer. Clifton, NJ: Humana Press; 1985.
21882: . Monoclonal antibodies and cancer therapy. New York: Liss; 1985.
21891: . Immunity to cancer II. New York: Liss; 1989.
22431: Metzgar RS, et al. Antigens of human pancreatic adenocarcinoma cells defined by murine monoclonal antibodies. Cancer Res. 42: 601-608, 1982. PubMed: 7034925
22757: Kim YW, et al. Characterization of clones of a human pancreatic adenocarcinoma cell line representing different stages of differentiation. Pancreas 4: 353-362, 1989. PubMed: 2734279
22758: Mullins TD, et al. Ultrastructural differentiation of sodium butyrate-treated human pancreatic adenocarcinoma cell lines. Pancreas 6: 578-587, 1991. PubMed: 1946315
23087: Worlock AJ, et al. Radiolocalization of human pancreatic tumors in athymic mice by monoclonal antibody DU-PAN 1. Cancer Res. 50: 7246-7251, 1990. PubMed: 2224857 |
